[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505841":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":36,"centralContacts":11,"locations":39,"responsibleParty":53,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":11,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":11,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":75,"overallStatus":77,"whyStopped":11,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Afimetoran, followed by famotidine + afimetoran","EXPERIMENTAL",null,[13,14],"Drug: Famotidine","Drug: Afimetoran",{"label":16,"type":10,"description":11,"interventionNames":17},"Famotidine + afimetoran, followed by afimetoran",[13,14],{"label":19,"type":10,"description":11,"interventionNames":20},"Afimetoran",[14],{"label":22,"type":10,"description":11,"interventionNames":23},"Famotidine, followed by afimetoran",[13,14],[25,32],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Famotidine","Specified dose on specified days",[9,16,22],[31],"Pepcid",{"type":26,"name":19,"description":28,"armGroupLabels":33,"otherNames":34},[19,9,16,22],[35],"BMS-986256",[37],{"name":5,"affiliation":5,"role":38},"STUDY_DIRECTOR",[40],{"facility":41,"status":11,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":11},"Local Institution - 0001","Nottingham","Nottinghamshire","NG11 6JS","United Kingdom","UK",{"type":48,"coordinates":49},"Point",[50,51],-1.15047,52.9536,{"lat":51,"lon":50},{"type":54,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100505841","phase-1-a-study-to-assess-the-effect-of-famotidine-on-the-drug-levels-of-afimetoran-in-healthy-participants-100505841",false,"NCT05866627","A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants","A Phase 1 Open-label, 2-Part Crossover Study to Assess the Effect of Acid-reducing Agent Famotidine on the Pharmacokinetics of Afimetoran (BMS-986256) in Healthy Participants","Inclusion Criteria:\n\n* Weight ≥ 50 kilograms (kg), at screening and first admission, and body mass index between 18.0 kilogram per square meter (kg\u002Fm\\^2) and 32.0 kg\u002Fm\\^2, inclusive, at screening.\n* A negative QuantiFERON-TB Gold test result at screening or documentation of a negative result within 3 months before screening.\n* Normal renal function at screening as evidenced by an estimated glomerular filtration rate (eGFR) ≥ 80 milliliter per minute (mL\u002Fmin)\u002F1.732 m\\^2 calculated with the Chronic Kidney Disease Epidemiology Collaboration formula.\n\nExclusion Criteria:\n\n* Any significant acute or chronic medical illness.\n* Current or recent (within 3 months of study drug administration) gastrointestinal (GI) disease that could impact upon the absorption of study treatment.\n* GI surgery, including cholecystectomy, that could impact upon the absorption of study treatment, at the investigator's discretion.",true,"ALL","18 Years","55 Years",{"count":67,"type":68},32,"ACTUAL","INTERVENTIONAL",[71],"PHASE1","The purpose of this study is to confirm there is no significant effect of gastric pH changes of famotidine on the drug levels of afimetoran in healthy participants.",[74],"Healthy Volunteers",[35,27,76],"Gastric pH","COMPLETED","2026-05-11",{"date":80,"type":68},"2026-05-13",{"date":82,"type":68},"2023-07-04",{"date":84,"type":68},"2023-09-29",{"name":5,"class":6},1]